Document Detail

Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance.
MedLine Citation:
PMID:  23286855     Owner:  NLM     Status:  In-Data-Review    
The management of treatment failure in patients with chronic hepatitis B, remains a clinical concern. Incomplete viral suppression and the emergence of drug resistance are key determinants of treatment failure. The correct choice of a potent first-line therapy to achieve sustained long-term suppression of viral replication provides the best chance of preventing treatment failure and drug resistance. Clinical studies have demonstrated that drugs with a high barrier to resistance have significantly lower rates of resistance compared with those with a low barrier to resistance. Management of treatment failure requires precise clinical and virological monitoring as well as early treatment intervention with appropriate noncross-resistant antivirals. Long-term surveillance of treatment efficacy and possible emergence of drug resistance is necessary in patients who have been sequentially treated with multiple antivirals. The identification of novel treatment targets remains a major research goal to improve the efficacy of current antiviral therapy through combination therapy regimens.
Fabien Zoulim; Stephen Locarnini
Related Documents :
23278775 - Efficacy of the 6-month thrice-weekly regimen in the treatment of new sputum smear-posi...
23446785 - Estimating renal function to reduce the risk of adverse drug reactions.
23210775 - New chemotherapeutic strategies against malaria, leishmaniasis, and trypanomiases.
2088365 - Determination of antitubercular drugs in human plasma by hplc through direct injection.
23278775 - Efficacy of the 6-month thrice-weekly regimen in the treatment of new sputum smear-posi...
16361085 - Pet neuroimaging of [11c]mirtazapine enantiomers in pigs.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Liver international : official journal of the International Association for the Study of the Liver     Volume:  33 Suppl 1     ISSN:  1478-3231     ISO Abbreviation:  Liver Int.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160857     Medline TA:  Liver Int     Country:  United States    
Other Details:
Languages:  eng     Pagination:  116-24     Citation Subset:  IM    
Copyright Information:
© 2012 John Wiley & Sons A/S.
INSERM, U1052, Cancer Research Center of Lyon, Lyon University, Lyon, France; Hepatology Department, Hospices Civils de Lyon, Lyon, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of therapy on the outcome of chronic hepatitis B.
Next Document:  The role of HBsAg quantification for monitoring natural history and treatment outcome.